Achievement of glycaemic control is associated with improvements in lipid profile with iGlarLixi versus iGlar: A post hoc analysis of the LixiLan-L trial.

Diabetes Obes Metab · 2019 · PMC6899526 · PMID 31423722

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

After accounting for baseline lipid values, lipid‐lowering drugs and weight change during the study, iGlarLixi showed a trend towards more favourable changes in absolute levels of TG, LDL‐C and TC compared with iGlar alone overall, based on LS mean differences in change from baseline between iGlarLixi and iGlar ( Figure S2A ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.